
    
      This is a multi-center, randomized, double-blind, placebo-controlled, 6 week study. The study
      consists of 3 separate sub-studies in which patients undergoing bilateral lower extremity
      peripheral artery atherectomy will receive one of three FDA approved drugs known to have
      beneficial effect on the risk of cardiovascular disease. Patients will be selected for the
      particular sub-study based on a series of entry criteria and then randomized to the
      particular agent or placebo for 6-weeks.
    
  